India, May 5 -- The Australian dollar strengthened against other major currencies in the late Asian session on Monday, after Australia's Prime Minister Anthony Albanese won a second three-year term in... Read More
India, May 5 -- V2X, Inc. (VVX) reported earnings for its first quarter that increased from the same period last year and beat the Street estimates. The company's bottom line totaled $8.11 million, o... Read More
India, May 5 -- HomesToLife Ltd (HTLM), a Singaporean furniture company, said on Monday that it has inked a deal with New Century International Homes Pte Ltd to acquire HTL Marketing Pte Ltd, a Singap... Read More
India, May 5 -- Sterling Construction Co. Inc. (STRL) released earnings for its first quarter that increased from last year and beat the Street estimates. The company's bottom line totaled $39.48 mil... Read More
India, May 5 -- Playa Hotels & Resorts N.V. (PLYA) revealed earnings for first quarter that decreased from last year but beat the Street estimates. The company's bottom line totaled $43.13 million, o... Read More
India, May 5 -- JAMES RIVER GROUP INC (JRVR) reported a profit for first quarter that decreased from last year and missed the Street estimates. The company's bottom line came in at $7.61 million, or ... Read More
India, May 5 -- Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program foll... Read More
India, May 5 -- The ISM Services Index and the PMI Composite Final for April will be the focus on Monday. The Federal Reserve's latest interest rate decisions and the latest earnings news will be of ... Read More
India, May 5 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Alvotech (ALVO) announced the FDA has approved SELARSDI injection as interchangeable with the refer... Read More
India, May 5 -- Aptose Biosciences Inc. (APTO), a clinical-stage precision oncology company, Monday reported encouraging data from Phase 1/2 TUSCANY study of tuspetinib in combination with standard-of... Read More